Prednisone Prevents Particle Induced Bone Loss in the Calvaria Mouse Model

Overview

Journal Heliyon

Specialty Social Sciences

Date 2021 Sep 2

PMID 34471710

Citations 2

Authors

Michael M Schundeln

Jakob Hoppner

Felix L Meyer

Wiebke Schmuck

Max D Kauther

Gero Hilken

Bodo Levkau

Martina Rauner

Corinna Grasemann

Affiliations

Soon will be listed here.

Abstract

Introduction: Glucocorticoids are essential in the treatment of many chronic inflammatory and malignant diseases but are known to have detrimental effects on bone. This study aimed to investigate the effects of prednisone on osteoclast functioning in the calvaria particle-induced bone loss mouse model.

Methods: 12-week-old male C57BL6/J mice received subcutaneously implanted prednisone (2.5 mg/d, 60 day release (n = 14)) or placebo pellets (n = 10). Osteolysis of the calvaria bone was induced two weeks later by application of ultra-high-molecular-weight polyethylene- (UHMWPE) particles to the dome (vs sham operation). The extent of osteolysis was determined histologically and by micro-computer tomography.

Results: Prednisone significantly inhibited particle-induced osteolysis in the skull. No significant difference in osteoclast numbers was seen in mice with prednisone vs placebo treatment. Prednisone treatment alone without particle application did not reduce bone mineral density or deterioration in bone microarchitecture parameters.

Conclusions: The calvaria particle-induced bone loss mouse model can be adapted to investigate osteoclast activity and the effect of prednisone on osteoclasts. In this preventive experimental design, the application of short-term low-dose prednisone has osteoprotective effects without measurable systemic side effects on bone parameters.

Citing Articles

The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).

Yee C, Meliadis C, Kaya S, Chang W, Alliston T Front Endocrinol (Lausanne). 2024; 15:1342938.

PMID: 39092287 PMC: 11291448. DOI: 10.3389/fendo.2024.1342938.

A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.

Okagu I, Ezeorba T, Aguchem R, Ohanenye I, Aham E, Okafor S Int J Mol Sci. 2022; 23(15).

PMID: 35955603 PMC: 9368769. DOI: 10.3390/ijms23158468.

References

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

Kukita T, Kukita A . Osteoclast differentiation antigen. Histol Histopathol. 1996; 11(3):821-30. View

Buttgereit F, Burmester G, Lipworth B . Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol. 2008; 5(1):18-9. DOI: 10.1038/ncprheum0963. View

Haugeberg G, Strand A, Kvien T, Kirwan J . Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med. 2005; 165(11):1293-7. DOI: 10.1001/archinte.165.11.1293. View

Kauther M, Bachmann H, Neuerburg L, Broecker-Preuss M, Hilken G, Grabellus F . Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis. BMC Musculoskelet Disord. 2011; 12:186. PMC: 3171722. DOI: 10.1186/1471-2474-12-186. View

Jia D, OBrien C, Stewart S, Manolagas S, Weinstein R . Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006; 147(12):5592-9. PMC: 1819400. DOI: 10.1210/en.2006-0459. View

Kim H, Zhao H, Kitaura H, Bhattacharyya S, Brewer J, Muglia L . Dexamethsone suppresses bone formation via the osteoclast. Adv Exp Med Biol. 2007; 602:43-6. DOI: 10.1007/978-0-387-72009-8_5. View

Boyce B, Xing L . Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139-46. PMC: 2413418. DOI: 10.1016/j.abb.2008.03.018. View

Atkins G, Haynes D, Howie D, Findlay D . Role of polyethylene particles in peri-prosthetic osteolysis: A review. World J Orthop. 2012; 2(10):93-101. PMC: 3302032. DOI: 10.5312/wjo.v2.i10.93. View

10.

Jiang H, Wang Y, Deng Z, Jin J, Meng J, Chen S . Construction and Evaluation of a Murine Calvarial Osteolysis Model by Exposure to CoCrMo Particles in Aseptic Loosening. J Vis Exp. 2018; (132). PMC: 5931316. DOI: 10.3791/56276. View

11.

Rizzoli R, Biver E . Glucocorticoid-induced osteoporosis: who to treat with what agent?. Nat Rev Rheumatol. 2014; 11(2):98-109. DOI: 10.1038/nrrheum.2014.188. View

12.

Korczowska I, Olewicz-Gawlik A, Trefler J, Hrycaj P, Lacki J . Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?. Clin Rheumatol. 2007; 27(5):565-72. DOI: 10.1007/s10067-007-0747-2. View

13.

Briot K, Geusens P, Em Bultink I, Lems W, Roux C . Inflammatory diseases and bone fragility. Osteoporos Int. 2017; 28(12):3301-3314. DOI: 10.1007/s00198-017-4189-7. View

14.

Garm Blavnsfeldt A, de Thurah A, Thomsen M, Tarp S, Langdahl B, Hauge E . The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials. Bone. 2018; 114:172-180. DOI: 10.1016/j.bone.2018.06.008. View

15.

Heidari B, Heidari P, Hajian-Tilaki K, Bayani M, Babaei M . Effect of long-term low dose prednisolone administration on bone mineral density: Relating to non-compliant women with rheumatoid arthritis. Caspian J Intern Med. 2018; 9(2):171-177. PMC: 5912226. DOI: 10.22088/cjim.9.2.171. View

16.

Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M . BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2008; 379(2):261-6. DOI: 10.1016/j.bbrc.2008.12.035. View

17.

von Knoch M, Jewison D, Sibonga J, Sprecher C, Morrey B, Loer F . The effectiveness of polyethylene versus titanium particles in inducing osteolysis in vivo. J Orthop Res. 2004; 22(2):237-43. DOI: 10.1016/j.orthres.2003.08.013. View

18.

Kirwan J . The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995; 333(3):142-6. DOI: 10.1056/NEJM199507203330302. View

19.

Clowes J, Riggs B, Khosla S . The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005; 208:207-27. DOI: 10.1111/j.0105-2896.2005.00334.x. View

20.

Parfitt A . Bone histomorphometry: standardization of nomenclature, symbols and units. Summary of proposed system. Bone Miner. 1988; 4(1):1-5. View